EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category  |
Confidence Level |
|---|
   3.5.3.18 | Diabetes Mellitus, Type 2 |
31733101 |
DDAH1 promoter -396 4N insertion variant is associated with increased risk of type 2 diabetes in a gender-dependent manner. |
causal interaction
unassigned |
3
0 |
| 3.5.3.18 | dimethylargininase deficiency |
19917889 |
Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. |
causal interaction
unassigned |
3
0 |
| 3.5.3.18 | dimethylargininase deficiency |
24260221 |
DDAH1 deficiency attenuates endothelial cell cycle progression and angiogenesis. |
causal interaction
ongoing research
unassigned |
4
2
0 |
| 3.5.3.18 | dimethylargininase deficiency |
26806551 |
DDAH1 deficiency promotes intracellular oxidative stress and cell apoptosis via a miR-21-dependent pathway in mouse embryonic fibroblasts. |
causal interaction
unassigned |
4
0 |
| 3.5.3.18 | dimethylargininase deficiency |
27181226 |
Dimethylarginine dimethylaminohydrolase-2 deficiency promotes vascular regeneration and attenuates pathological angiogenesis. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.18 | Hyperhomocysteinemia |
17895252 |
Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia. |
causal interaction
therapeutic application
unassigned |
1
2
0 |
| 3.5.3.18 | Hypertension |
33214214 |
Specific Lowering of Asymmetric Dimethylarginine by Pharmacological Dimethylarginine Dimethylaminohydrolase Improves Endothelial Function, Reduces Blood Pressure and Ischemia-Reperfusion Injury. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
2
2
0 |
| 3.5.3.18 | Hypertension |
34533401 |
Overexpression of dimethylarginine dimethylaminohydrolase 1 protects from angiotensin II - induced cardiac hypertrophy and vascular remodeling. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
3
3
0 |
| 3.5.3.18 | Hypertrophy, Right Ventricular |
21641341 |
Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. |
causal interaction
therapeutic application
unassigned |
3
1
0 |
| 3.5.3.18 | Kidney Diseases |
21136910 |
The glomerular proteome in a model of chronic kidney disease. |
causal interaction
unassigned |
1
0 |
